Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770333 | 0.89 | THRB (0.52) | KDM4EMAPTTHRBGPR119DPP4 | |
| SCHEMBL19107652 | 0.89 | THRB (0.49) | KDM4EMAPTTHRBGPR119DPP4 | |
| SCHEMBL17303745 | 0.88 | KDM4E (0.48) | KDM4EMAPTTHRBGPR119HPGD | |
| SCHEMBL17304114 | 0.87 | MAPT (0.47) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL17304115 | 0.87 | KDM4E (0.47) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL1770494 | 0.87 | KDM4E (0.43) | KDM4EMAPTTHRBGPR119KMT2A | |
| SCHEMBL17303744 | 0.86 | PDE4B (0.48) | KDM4EMAPTTHRBGPR119DPP4 | |
| SCHEMBL17303751 | 0.85 | MAPT (0.46) | KDM4EMAPTTHRBGPR119DPP4 | |
| SCHEMBL17304126 | 0.85 | KDM4E (0.46) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL1012726 | 0.85 | MAPT (0.46) | KDM4EMAPTTHRBGPR119PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2018-07-17 | — | — | US | disclosed |
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2013-11-21 | — | — | US | disclosed |
| US-8519129-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-08-27 | — | — | US | disclosed |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| EP-2318392-A2 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010002655-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | ALK, BRAF, ABL1 | KDM4E 497/4885MAPT 2610/4885THRB 1543/4885 |
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IGF1R, IRS1, IP6K1 | KDM4E 1272/4885MAPT 3482/4885THRB 1056/4885 |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | ALK, BRAF, ABL1 | KDM4E 497/4885MAPT 2610/4885THRB 1543/4885 |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, TYMP, PDXK | KDM4E 1822/4885MAPT 4046/4885THRB 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.